SILENCE THERAP. SP.ADR/1 (XRP2) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SILENCE THERAP. SP.ADR/1 (XRP2) has a cash flow conversion efficiency ratio of -0.277x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.29 Million ≈ $-20.21 Million USD) by net assets (€62.30 Million ≈ $72.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SILENCE THERAP. SP.ADR/1 balance sheet quality to measure how much of total assets are equity-financed.
SILENCE THERAP. SP.ADR/1 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how SILENCE THERAP. SP.ADR/1's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check XRP2 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
SILENCE THERAP. SP.ADR/1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SILENCE THERAP. SP.ADR/1 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tudor Gold Corp
V:TUD
|
-0.003x |
|
888 Holdings plc
F:C8V
|
-0.007x |
|
P.C.B Tec
TA:PCBT
|
0.032x |
|
NEOWIZ
KQ:095660
|
0.074x |
|
KOSES Co.Ltd
KQ:089890
|
0.044x |
|
Giantplus Technology Co Ltd
TW:8105
|
0.004x |
|
Servotech Power Systems Limited
NSE:SERVOTECH
|
0.050x |
|
Baazar Style Retail Limited
NSE:STYLEBAAZA
|
0.240x |
Annual Cash Flow Conversion Efficiency for SILENCE THERAP. SP.ADR/1 (2021–2025)
The table below shows the annual cash flow conversion efficiency of SILENCE THERAP. SP.ADR/1 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see SILENCE THERAP. SP.ADR/1 (XRP2) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €62.30 Million ≈ $72.84 Million |
€-62.27 Million ≈ $-72.80 Million |
-0.999x | -98.04% |
| 2024-12-31 | €134.02 Million ≈ $156.69 Million |
€-67.64 Million ≈ $-79.08 Million |
-0.505x | +77.56% |
| 2023-12-31 | €21.99 Million ≈ $25.71 Million |
€-49.46 Million ≈ $-57.83 Million |
-2.249x | -5.31% |
| 2022-12-31 | €26.71 Million ≈ $31.23 Million |
€-57.04 Million ≈ $-66.69 Million |
-2.136x | -367.53% |
| 2021-12-31 | €11.51 Million ≈ $13.45 Million |
€9.19 Million ≈ $10.74 Million |
0.798x | -- |
About SILENCE THERAP. SP.ADR/1
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more